Related references
Note: Only part of the references are listed.SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Carmine Fedele et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition
Hitendra S. Solanki et al.
CLINICAL CANCER RESEARCH (2021)
PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis
B. Li et al.
Journal of Thoracic Oncology (2021)
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Meagan B. Ryan et al.
CLINICAL CANCER RESEARCH (2020)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A06 Tri-complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Preclinical Models of NSCLC
R. Nichols et al.
Journal of Thoracic Oncology (2020)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
Naiara Santana-Codina et al.
CELL REPORTS (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
P.A. Jänne et al.
EUROPEAN JOURNAL OF CANCER (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Hao Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers
Emiko Kinoshita-Kikuta et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Sandra Misale et al.
CLINICAL CANCER RESEARCH (2019)
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12c overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Christopher J. Schulze et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
Yijun Gao et al.
CANCER DISCOVERY (2018)
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B. Fell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Zbyslaw Sondka et al.
NATURE REVIEWS CANCER (2018)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Mei Zeng et al.
CELL CHEMICAL BIOLOGY (2017)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
Leanne G. Ahronian et al.
CANCER DISCOVERY (2015)
Anchored multiplex FOR for targeted next-generation sequencing
Zongli Zheng et al.
NATURE MEDICINE (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
